The calculation workspace

GLP-1 Weight Loss Timeline

See how published clinical-trial average weight-loss curves map onto a starting weight across major GLP-1 and dual/triple-agonist studies.

Every endpoint comes from a peer-reviewed trial (STEP 1, STEP UP, SURMOUNT-1, SUSTAIN FORTE, SURPASS-2, SCALE, and TRIUMPH-1). Trial means describe study groups, not guaranteed individual outcomes.

Medical Supervision Required:Peptide Tracker is for private logging, reminders, inventory records, and education. It is not medical advice, dosing instruction, prescribing guidance, diagnosis, or a substitute for a qualified healthcare professional.
Trial mean loss0%
Mean weight change0lb
Endpoint average0lb
Published clinical trial mean weight trajectory versus placebo

MilestoneModeled % changeCumulative lossReference weight

These trials differed in duration, baseline populations (with or without type 2 diabetes), and statistical estimands. Direct comparisons are valid only within head-to-head studies such as SURMOUNT-5 or SURPASS-2.

Medication & DoseTrialDurationMean Weight ChangePlacebo
Wegovy 2.4 mgSTEP 1 (no T2D)68 weeks-14.9%-2.4%
Wegovy 7.2 mgSTEP UP (no T2D)72 weeks-18.7%-3.9%
Zepbound 5 / 10 / 15 mgSURMOUNT-1 (no T2D)72 weeks-15.0% / -19.5% / -20.9%-3.1%
Ozempic 2 mgSUSTAIN FORTE (T2D)40 weeks~-7.0% (~6.9 kg)Active comparator
Mounjaro 15 mgSURPASS-2 (T2D)40 weeks~-12.0% (11.2 kg)Active comparator
Saxenda 3.0 mgSCALE (no T2D)56 weeks-8.0%-2.6%
Orforglipron 45 mgPhase 2 (no T2D)36 weeks-14.7%-2.3%
Retatrutide 12 mg (investigational)TRIUMPH-1 ITT80 weeks-25.0%-2.1%

Weight on the scale combines fat mass and lean mass. Clinical body-composition sub-studies show that roughly 25% to 40% of weight lost during rapid calorie restriction can come from lean tissue unless paired with adequate protein and resistance exercise. Read GLP-1 and Muscle Loss for the clinical evidence on body composition during treatment.

Add this calculator to your website with the code below.

Get embed code

Attribution is included. These are calculation and tracking tools, not medical advice.

  • How much weight do people lose on Wegovy vs Zepbound in clinical trials?

    In separate 68- to 72-week trials of adults with obesity and no diabetes, Wegovy 2.4 mg averaged 14.9% weight loss (STEP 1) and Wegovy 7.2 mg averaged 18.7% (STEP UP), while Zepbound averaged 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg (SURMOUNT-1). In the open-label head-to-head SURMOUNT-5 trial, tirzepatide (10–15 mg) averaged 20.2% vs 13.7% for semaglutide (1.7–2.4 mg).

  • Why is average weight loss smaller in Ozempic and Mounjaro trials?

    Ozempic and Mounjaro trials (such as SUSTAIN FORTE and SURPASS-2) enrolled adults with type 2 diabetes and ran for 40 weeks rather than 68–72 weeks. Across GLP-1 trials, participants with type 2 diabetes consistently lose less weight on average than participants without diabetes.

  • Is this calculator a personal prediction of how much weight I will lose?

    No. Every curve reflects a published group average from a specific clinical trial that included structured nutrition and physical-activity counseling. Individual responses range widely — some people lose more than the mean, while others lose less or discontinue due to side effects.

  • Why does the curve slow down over time?

    In virtually every incretin trial, weight loss is steepest during the first 6 to 9 months as doses escalate and energy intake drops, then gradually flattens into a plateau around 12 to 18 months as resting energy expenditure adjusts to a lower body mass.

  • Is retatrutide FDA-approved?

    No. Retatrutide is an investigational Eli Lilly triple agonist (GIP, GLP-1, and glucagon). Its Phase 2 and TRIUMPH-1 Phase 3 results are shown strictly as published research data, not an approved treatment.